Published in EMBO J on October 28, 2004
Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer (2009) 4.66
Transcription factor and microRNA motif discovery: the Amadeus platform and a compendium of metazoan target sets. Genome Res (2008) 3.09
Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J (2007) 2.75
Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet (2013) 2.59
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. Proc Natl Acad Sci U S A (2005) 2.19
The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov (2015) 2.15
The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer (2013) 1.93
The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev (2012) 1.92
Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res (2011) 1.89
Discovering functional transcription-factor combinations in the human cell cycle. Genome Res (2005) 1.53
The human synMuv-like protein LIN-9 is required for transcription of G2/M genes and for entry into mitosis. EMBO J (2006) 1.51
Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets. Cell Cycle (2011) 1.46
Wide-ranging functions of E2F4 in transcriptional activation and repression revealed by genome-wide analysis. Nucleic Acids Res (2011) 1.43
Cyclic expression of the voltage-gated potassium channel KV10.1 promotes disassembly of the primary cilium. EMBO Rep (2016) 1.43
A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription. Genes Dev (2004) 1.42
MicroRNA-302 increases reprogramming efficiency via repression of NR2F2. Stem Cells (2013) 1.41
The MPS1 family of protein kinases. Annu Rev Biochem (2012) 1.38
Epigenetic regulation of gene expression by Drosophila Myb and E2F2-RBF via the Myb-MuvB/dREAM complex. Genes Dev (2008) 1.36
Distinctions in the specificity of E2F function revealed by gene expression signatures. Proc Natl Acad Sci U S A (2005) 1.34
Opposing roles of E2Fs in cell proliferation and death. Cancer Biol Ther (2004) 1.33
The CHR promoter element controls cell cycle-dependent gene transcription and binds the DREAM and MMB complexes. Nucleic Acids Res (2011) 1.30
c-Myb contributes to G2/M cell cycle transition in human hematopoietic cells by direct regulation of cyclin B1 expression. Mol Cell Biol (2007) 1.26
E2F7 represses a network of oscillating cell cycle genes to control S-phase progression. Nucleic Acids Res (2011) 1.26
Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity. Mol Cell Biol (2006) 1.22
Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation. BMC Bioinformatics (2008) 1.19
Genome-wide analysis of transcription factor E2F1 mutant proteins reveals that N- and C-terminal protein interaction domains do not participate in targeting E2F1 to the human genome. J Biol Chem (2011) 1.18
Subunits of the heterotrimeric transcription factor NF-Y are imported into the nucleus by distinct pathways involving importin beta and importin 13. Mol Cell Biol (2005) 1.15
RB's original CIN? Genes Dev (2010) 1.14
Stem cell pluripotency: a cellular trait that depends on transcription factors, chromatin state and a checkpoint deficient cell cycle. J Cell Physiol (2009) 1.13
In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene (2008) 1.13
E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes Dev (2012) 1.12
Allegro: analyzing expression and sequence in concert to discover regulatory programs. Nucleic Acids Res (2009) 1.11
Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Oncotarget (2010) 1.07
Genome-wide location analysis and expression studies reveal a role for p110 CUX1 in the activation of DNA replication genes. Nucleic Acids Res (2007) 1.06
Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle. Nucleic Acids Res (2006) 1.05
A B-Myb complex containing clathrin and filamin is required for mitotic spindle function. EMBO J (2008) 1.05
Merging high-quality biochemical fractionation with a refined flow cytometry approach to monitor nucleocytoplasmic protein expression throughout the unperturbed mammalian cell cycle. Nat Protoc (2013) 1.05
YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst (2011) 1.04
Retracted Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J Biol Chem (2008) 1.04
Small molecule screening in zebrafish: an in vivo approach to identifying new chemical tools and drug leads. Cell Commun Signal (2010) 1.03
E2F4 regulates a stable G2 arrest response to genotoxic stress in prostate carcinoma. Oncogene (2006) 1.03
Patterns of cell signaling pathway activation that characterize mammary development. Development (2008) 1.02
CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP, and MKLP1 in S phase. Mol Cell Biol (2008) 1.00
Long noncoding RNA PANDA and scaffold-attachment-factor SAFA control senescence entry and exit. Nat Commun (2014) 0.99
p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes. Mol Cell Biol (2008) 0.99
p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes. Oncogene (2013) 0.98
Lin9, a subunit of the mammalian DREAM complex, is essential for embryonic development, for survival of adult mice, and for tumor suppression. Mol Cell Biol (2010) 0.97
E2f1-3 are critical for myeloid development. J Biol Chem (2010) 0.97
Regulation of human endometrial stromal proliferation and differentiation by C/EBPβ involves cyclin E-cdk2 and STAT3. Mol Endocrinol (2012) 0.97
The lin-35/Rb and RNAi pathways cooperate to regulate a key cell cycle transition in C. elegans. BMC Dev Biol (2007) 0.97
Integrative bioinformatics analysis of transcriptional regulatory programs in breast cancer cells. BMC Bioinformatics (2008) 0.96
Dynamic epitope expression from static cytometry data: principles and reproducibility. PLoS One (2012) 0.96
A combinatorial mechanism for determining the specificity of E2F activation and repression. Oncogene (2009) 0.94
E2F4 function in G2: maintaining G2-arrest to prevent mitotic entry with damaged DNA. Cell Cycle (2007) 0.94
Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol (2014) 0.94
E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma. Cancer Res (2009) 0.92
Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching. Mol Cell Biol (2012) 0.91
En masse nascent transcription analysis to elucidate regulatory transcription factors. Nucleic Acids Res (2006) 0.90
Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem (2010) 0.90
E2f6 and Bmi1 cooperate in axial skeletal development. Dev Dyn (2008) 0.89
Unraveling transcriptional control and cis-regulatory codes using the software suite GeneACT. Genome Biol (2006) 0.89
The RIP140 gene is a transcriptional target of E2F1. PLoS One (2012) 0.89
The B-MYB transcriptional network guides cell cycle progression and fate decisions to sustain self-renewal and the identity of pluripotent stem cells. PLoS One (2012) 0.88
Mitosis-specific promoter of the alfalfa cyclin-dependent kinase gene (Medsa;CDKB2;1) is activated by wounding and ethylene in a non-cell division-dependent manner. Plant Physiol (2006) 0.88
Gene set-based module discovery in the breast cancer transcriptome. BMC Bioinformatics (2009) 0.88
A central role for TRPS1 in the control of cell cycle and cancer development. Oncotarget (2014) 0.87
Transcriptional control of mitosis: deregulation and cancer. Front Endocrinol (Lausanne) (2015) 0.87
A new E6/P63 pathway, together with a strong E7/E2F mitotic pathway, modulates the transcriptome in cervical cancer cells. J Virol (2007) 0.87
Neuroprotective changes of striatal degeneration-related gene expression by acupuncture in an MPTP mouse model of Parkinsonism: microarray analysis. Cell Mol Neurobiol (2010) 0.87
B-Myb, cancer, senescence, and microRNAs. Cancer Res (2011) 0.86
Effects of excretory/secretory products from Clonorchis sinensis and the carcinogen dimethylnitrosamine on the proliferation and cell cycle modulation of human epithelial HEK293T cells. Korean J Parasitol (2008) 0.86
MYBL2, a link between proliferation and differentiation in maturing colon epithelial cells. J Cell Physiol (2011) 0.86
Repression of androgen receptor transcription through the E2F1/DNMT1 axis. PLoS One (2011) 0.86
Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis. Cancers (Basel) (2014) 0.85
MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife (2013) 0.85
E2F inhibition synergizes with paclitaxel in lung cancer cell lines. PLoS One (2014) 0.83
RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis. J Biol Chem (2007) 0.83
E2F activators signal and maintain centrosome amplification in breast cancer cells. Mol Cell Biol (2014) 0.83
MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer. Am J Cancer Res (2015) 0.83
TREMOR--a tool for retrieving transcriptional modules by incorporating motif covariance. Nucleic Acids Res (2007) 0.82
Peroxisome proliferator-activated receptor β/δ cross talks with E2F and attenuates mitosis in HRAS-expressing cells. Mol Cell Biol (2012) 0.82
Role of Cdk1 in DNA damage-induced G1 checkpoint abrogation by the human papillomavirus E7 oncogene. Cell Cycle (2014) 0.82
A novel E2F-like protein involved in transcriptional activation of cyst wall protein genes in Giardia lamblia. J Biol Chem (2011) 0.81
Periodic expression of Kv10.1 driven by pRb/E2F1 contributes to G2/M progression of cancer and non-transformed cells. Cell Cycle (2016) 0.80
Expression of human eukaryotic initiation factor 3f oscillates with cell cycle in A549 cells and is essential for cell viability. Cell Div (2010) 0.80
Deletion of the p107/p130-binding domain of Mip130/LIN-9 bypasses the requirement for CDK4 activity for the dissociation of Mip130/LIN-9 from p107/p130-E2F4 complex. Exp Cell Res (2009) 0.80
Novel Molecular Markers for Breast Cancer. Biomark Cancer (2016) 0.80
B-Myb promotes S-phase independently of its sequence-specific DNA binding activity and interacts with polymerase delta-interacting protein 1 (Pdip1). Cell Cycle (2012) 0.79
Deriving transcriptional programs and functional processes from gene expression databases. Bioinformatics (2012) 0.79
Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1. Oncotarget (2015) 0.79
ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget (2015) 0.79
MicroRNAs and lncRNAs in senescence: A re-view. IUBMB Life (2015) 0.79
Robustness of cell cycle control and flexible orders of signaling events. Sci Rep (2015) 0.78
A chrysin derivative suppresses skin cancer growth by inhibiting cyclin-dependent kinases. J Biol Chem (2013) 0.78
A data-driven, mathematical model of mammalian cell cycle regulation. PLoS One (2014) 0.78
Deregulation of Rb-E2F1 axis causes chromosomal instability by engaging the transactivation function of Cdc20-anaphase-promoting complex/cyclosome. Mol Cell Biol (2014) 0.78
ARF-induced downregulation of Mip130/LIN-9 protein levels mediates a positive feedback that leads to increased expression of p16Ink4a and p19Arf. Oncogene (2010) 0.78
Feedback regulation between atypical E2Fs and APC/CCdh1 coordinates cell cycle progression. EMBO Rep (2016) 0.78
lin9 is required for mitosis and cell survival during early zebrafish development. J Biol Chem (2009) 0.78
Transcriptional regulatory networks in Saccharomyces cerevisiae. Science (2002) 43.52
The regulation of E2F by pRB-family proteins. Genes Dev (1998) 12.77
E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev (2002) 10.06
Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev (2000) 6.07
Coordination of growth and cell division in the Drosophila wing. Cell (1998) 5.93
Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol (2001) 5.03
Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ (1998) 4.38
Cell cycle regulation of the human cdc2 gene. EMBO J (1992) 3.69
The myb gene family in cell growth, differentiation and apoptosis. Oncogene (1999) 3.28
E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev (2002) 3.12
Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev (1999) 2.73
Role of the CCAAT-binding protein CBF/NF-Y in transcription. Trends Biochem Sci (1998) 2.71
Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes is based on a common mechanism of transcriptional repression. EMBO J (1995) 2.67
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene (2002) 2.39
E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev (1995) 1.95
In vivo structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression. Mol Cell Biol (1995) 1.93
Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76
p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem (1999) 1.65
Myb proteins in life, death and differentiation. Curr Opin Genet Dev (1998) 1.55
Nucleotide preferences in sequence-specific recognition of DNA by c-myb protein. Nucleic Acids Res (1991) 1.53
DNA binding activity and transcriptional activator function of the human B-myb protein compared with c-MYB. J Biol Chem (1990) 1.43
E2F-mediated growth regulation requires transcription factor cooperation. J Biol Chem (1997) 1.36
Cell cycle-dependent regulation of the cyclin B1 promoter. J Biol Chem (1995) 1.36
Combinatorial gene control involving E2F and E Box family members. EMBO J (2004) 1.35
c-myb transactivates cdc2 expression via Myb binding sites in the 5'-flanking region of the human cdc2 gene. J Biol Chem (1993) 1.34
Cell cycle regulation of cdc25C transcription is mediated by the periodic repression of the glutamine-rich activators NF-Y and Sp1. Nucleic Acids Res (1995) 1.31
Myb controls G(2)/M progression by inducing cyclin B expression in the Drosophila eye imaginal disc. EMBO J (2002) 1.29
Cell cycle-regulated repression of B-myb transcription: cooperation of an E2F site with a contiguous corepressor element. Nucleic Acids Res (1996) 1.25
Cell-cycle regulation of gene expression by transcriptional repression. Trends Genet (1997) 1.19
The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties. Oncogene (1998) 1.13
Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2F1 promoter. Oncogene (2003) 1.11
A new model of cell cycle-regulated transcription: repression of the cyclin A promoter by CDF-1 and anti-repression by E2F. Oncogene (1998) 1.07
Three CCAAT-boxes and a single cell cycle genes homology region (CHR) are the major regulating sites for transcription from the human cyclin B2 promoter. Gene (2003) 1.04
Cell cycle-dependent usage of transcriptional start sites. A novel mechanism for regulation of cyclin B1. J Biol Chem (1998) 1.02
Transcriptional activation of the p34cdc2 gene by cdc2 promoter binding factor/nuclear factor-Y in fetal rat ventricular myocytes. Circ Res (1998) 0.86
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest (2008) 2.18
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89
Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76
Embracing the complexity of genomic data for personalized medicine. Genome Res (2006) 1.75
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature (2010) 1.73
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72
Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem (2001) 1.70
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS One (2012) 1.60
Therapeutic applications of DNA and RNA aptamers. Oligonucleotides (2009) 1.59
Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol (2006) 1.57
Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci U S A (2002) 1.51
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res (2012) 1.47
The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells. J Biol Chem (2003) 1.46
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
Retracted An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One (2008) 1.45
Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS One (2008) 1.44
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription. Genes Dev (2004) 1.42
Balancing the decision of cell proliferation and cell fate. Cell Cycle (2009) 1.36
Combinatorial gene control involving E2F and E Box family members. EMBO J (2004) 1.35
Distinctions in the specificity of E2F function revealed by gene expression signatures. Proc Natl Acad Sci U S A (2005) 1.34
Origin of bistability underlying mammalian cell cycle entry. Mol Syst Biol (2011) 1.32
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol (2004) 1.29
Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A (2009) 1.26
Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res (2009) 1.26
Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res (2003) 1.26
Network calisthenics: control of E2F dynamics in cell cycle entry. Cell Cycle (2011) 1.25
Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res (2010) 1.24
Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol (2010) 1.20
An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res (2009) 1.19
Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res (2008) 1.19
Jab1 is a specificity factor for E2F1-induced apoptosis. Genes Dev (2006) 1.17
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther (2011) 1.16
Nucleotide bias observed with a short SELEX RNA aptamer library. Nucleic Acid Ther (2011) 1.15
RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther (2007) 1.14
An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer. BMC Genomics (2008) 1.14
Genomic strategies for personalized cancer therapy. Hum Mol Genet (2007) 1.14
Retracted Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood (2005) 1.12
Utilization of genomic signatures to identify phenotype-specific drugs. PLoS One (2009) 1.12
Cell-specific aptamers for targeted therapies. Methods Mol Biol (2009) 1.11
Molecular evidence for arterial repair in atherosclerosis. Proc Natl Acad Sci U S A (2005) 1.09
Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv (2013) 1.09
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A (2009) 1.09
Diagnosis of partial body radiation exposure in mice using peripheral blood gene expression profiles. PLoS One (2010) 1.07
Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. Mol Ther (2002) 1.06
Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv (2010) 1.05
Gene expression profiling for prediction of clinical characteristics of breast cancer. Recent Prog Horm Res (2003) 1.04
Stochastic E2F activation and reconciliation of phenomenological cell-cycle models. PLoS Biol (2010) 1.03
Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC. Mol Cell (2011) 1.03
Temporal control of cell cycle gene expression mediated by E2F transcription factors. Cell Cycle (2005) 1.03
Patterns of cell signaling pathway activation that characterize mammary development. Development (2008) 1.02
Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci U S A (2007) 1.01
Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res (2010) 1.01
Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem Biophys Res Commun (2005) 1.00
Phylogenetic simulation of promoter evolution: estimation and modeling of binding site turnover events and assessment of their impact on alignment tools. Genome Biol (2007) 0.99
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res (2009) 0.98
Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg Med Chem (2011) 0.98
Utilization of genomic signatures to direct use of primary chemotherapy. Curr Opin Genet Dev (2008) 0.96
Gene expression phenotypes of oncogenic signaling pathways. Cell Cycle (2003) 0.95
Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med (2011) 0.94
SIGNATURE: a workbench for gene expression signature analysis. BMC Bioinformatics (2011) 0.94
The Rb-related p130 protein controls telomere lengthening through an interaction with a Rad50-interacting protein, RINT-1. Mol Cell (2006) 0.93
Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression. J Biol Chem (2013) 0.93
Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. J Mol Med (Berl) (2010) 0.92
Integrating factor analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors. BMC Med Genomics (2011) 0.91
A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genet (2009) 0.90
Multimodal regulation of E2F1 gene expression by progestins. Mol Cell Biol (2010) 0.90
Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med (2010) 0.87
Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells. Methods Mol Biol (2015) 0.87
Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80. N Engl J Med (2011) 0.87